Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.64 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | C1S | P09871 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335492 | 0.83 | CTBP2 (0.62) | CTBP2HTTCA1CA2SAE1 | |
| SCHEMBL8993811 | 0.82 | CTBP2 (0.53) | CTBP2F2HTTPLGPRSS1 | |
| Hydrochloric Acid SCHEMBL7981327 | 0.82 | CTBP2 (0.61) | CTBP2HTTCA1CA2SAE1 | |
| SCHEMBL29236556 | 0.82 | CTBP2 (0.61) | CTBP2HTTCA1CA2SAE1 | |
| SCHEMBL6937899 | 0.81 | CTBP2 (0.59) | CTBP2HTTCA1CA2SAE1 | |
| SCHEMBL4579428 | 0.81 | CTBP2 (0.60) | CTBP2HTTCA1CA2SAE1 | |
| SCHEMBL6564262 | 0.79 | CTBP2 (0.58) | CTBP2HTTCA1CA2SAE1 | |
| SCHEMBL8185095 | 0.78 | HTT (0.62) | CTBP2HTTCA2SAE1UBA2 | |
| SCHEMBL9641208 | 0.78 | CTBP2 (0.57) | CTBP2HTTSAE1UBA2CES2 | |
| SCHEMBL5080688 | 0.78 | CTBP2 (0.57) | CTBP2HTTCA1CA2SAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1038953-B1 | Stereoselective transaminase, gene encoding said protein and use thereof | SUMITOMO CHEMICAL CO (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6727083-B2 | PROTEIN FOR USE IN THE GENERATION OF BRONCHODILATING AGENT, PESTICIDES, FUNGICIDE, HERBICIDES AND FOR USE IN THE TREATMENT OF DIABETES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-27 | — | — | US | disclosed |
| US-20020127664-A1 | Protein capable of catalyzing transamination stereoselectively, gene encoding said protein and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-09-12 | — | — | US | disclosed |
| US-6413752-B1 | AMINO ACID SEQUENCE OF ENZYME WHICH CONVERTS ACETOPHENONE TO OPTICALLY ACTIVE 1-PHENYLETHYLAMINE IN PRESENCE OF RACEMIC SEC-BUTYLAMINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6200976-B1 | FOR TREATING THROMBOSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-1071669-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| EP-1060166-A1 | FIVE-MEMBERED, BENZO-CONDENSED HETEROCYCLES USED AS ANTITHROMBOTIC AGENTS | Boehringer Ingelheim Pharma KG (DE) | 2000-12-20 | — | — | EP | disclosed |
| EP-1038953-A1 | Stereoselective transaminase, gene encoding said protein and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-09-27 | — | — | EP | disclosed |
| US-6114532-A | ANTICOAGULANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-05 | — | — | US | disclosed |
| WO-1999054313-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999040072-A1 | FIVE-MEMBERED, BENZO-CONDENSED HETEROCYCLES USED AS ANTITHROMBOTIC AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-08-12 | — | — | WO | disclosed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0073143-B1 | NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES | Ryan, James Walter (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | disclosed |
| EP-0073143-A2 | Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides | Ryan, James Walter (US) | 1983-03-02 | — | — | EP | disclosed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127664-A1 | Protein capable of catalyzing transamination stereoselectively, gene encoding said protein and use thereof | THEM6, FARSB, FARSA | CTBP2 247/4885F2 4029/4885HTT 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.